BridgeMD
New treatment option for Bronchiectasis Adult
Official title REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study
ClinicalTrials.gov ID: NCT06987214
What this study is testing
What is REGEND001 Autologous Basal Layer Stem Cell Suspension?
REGEND001 Autologous Basal Layer Stem Cell Suspension is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for bronchiectasis adult.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous basal layer stem cell transplantation therapy, in patients with chronic structural lung disease (bronchiectasis). The treatment involves harvesting bronchial basal layer stem cells from the patient, expanding them ex vivo, and reintroducing them via bronchoscopic infusion to repair damaged lung tissue.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 25 to 80
You may be able to join if
- Age 25-80 years.
- Confirmed diagnosis of bronchiectasis.
- FEV1 ≥35% predicted; DLCO ≥30% and \<80% predicted.
You likely can't join if
- Pregnancy, lactation, or plans for pregnancy within 1 year.
- Active malignancy or history of malignancy.
- Positive serology for HIV, HBV, HCV, or syphilis.
The study team makes the final eligibility decision.
Where it's taking place
- Qionghai, Hainan, China
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 25 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Qionghai, Hainan, China; Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.